Skip to main content
Equibles

Dan Brennan

Analyst

TD Cowen

Analyst

Cowen

Analyst

UBS

CFO

Catalyst Pharmaceuticals, Inc.

Equibles does not estimate personal net worth.

About Dan Brennan

Dan Brennan is recorded as Analyst at TD Cowen, Analyst at Cowen, Analyst at UBS and CFO at Catalyst Pharmaceuticals, Inc.. Dan Brennan has spoken on 57 earnings calls and 2 other investor events across 23 companies, most recently for Thermo Fisher Scientific Inc. on October 21, 2026. Those appearances were for Guardant Health, Inc. (GH), Natera, Inc. (NTRA), Revvity, Inc. (RVTY), Agilent Technologies, Inc. (A), Avantor, Inc. (AVTR) and 18 other companies. Catalyst Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other companies whose calls Dan Brennan spoke on are classified in the Healthcare sector.

Dan Brennan on recent calls

“Maybe the first one just on how the quarter came in versus expectations.”
Analyst — TD Cowen, Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026 ·
“Maybe just going back to China for my first one. So just, you know, China was substantially above what you guys expected, 9% versus flat. So on 20% of your revenues, that's almost the whole level of the beat.”
Analyst — TD Cowen, Agilent Technologies, Inc. Q3 FY2026 Earnings Call ·
“Maybe back to the first question in terms of, I know Austin was talking a lot about as you guys migrate your focus, maybe towards more, start to think about more execution, delivery of volumes.”
Analyst — TD Cowen, Sera Prognostics, Inc. Q2 FY2026 Earnings Call ·
“Maybe just the first one on the quarter itself on the tap strength and maybe kind of unpacking a little bit consumables and instruments. So TAP drove, like, really strong growth, some upside.”
Analyst — TD Cowen, Alamar Biosciences, Inc. Q2 Earnings Call ·
“Maybe I'll just ask two and then kind of mute and listen. Maybe on the first one, Tiri, I think you mentioned up front to, I think, Jack's question on the strategic plan, both internal efficiency gains and also looking at, you know, potential strategic acquirers to maximize value.”
Analyst — TD Cowen, QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast ·

Affiliation history

  • TD Cowen

    Analyst

    Source not stated

    Current

  • Cowen

    Analyst

    Source not stated

    Current

  • UBS

    Analyst

    Source not stated

    Current

  • Catalyst Pharmaceuticals, Inc.

    CFO

    Source not stated

    Current

Company network

Catalyst Pharmaceuticals, Inc.

Current role

Biotechnology · Healthcare

CFO

Recent activity

Show 47 earlier activities